Drug intelligence / Profile preview

dexrazoxane + epirubicin + filgrastim + paclitaxel

Development stage: Preclinical
Lead developer: Imperial Cancer Research Fund
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination chemotherapy regimen consisting of dexrazoxane (a cardioprotective agent), epirubicin (an anthracycline chemotherapeutic), filgrastim (a granulocyte colony-stimulating factor), and paclitaxel (a taxane chemotherapeutic). This combination likely uses dexrazoxane to protect against epirubicin-induced cardiotoxicity, while filgrastim helps manage neutropenia caused by the chemotherapy agents.

Targets

TOP2A (DNA topoisomerase II)CSF3R (Granulocyte colony-stimulating factor receptor)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on dexrazoxane + epirubicin + filgrastim + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexrazoxane + epirubicin + filgrastim + paclitaxel.

Explore the full profile